http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8796293-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a08b31ad3196a72d724efff0f7779c28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81c150af8961fd5ae4f74c3565019f3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60b8fd5e85b894143f849bfbc0f7ffb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b70512b2076a2759fccaecf9fe962d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4856e400671f3d8b0ac4a1b45e032087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0026d3b75c46d7c5157b131716f3603 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7496a5d8015a2912a24ede49ee539b8c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2007-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1a2ed45af43821299019cadb393c6cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5944a42b309bb2c52467fdff8b8aa42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc42225824a4b1e625750a67cc93bbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b46da7d7bac172a2c0efe01dbd952ac |
| publicationDate | 2014-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8796293-B2 |
| titleOfInvention | Purine and deazapurine derivatives as pharmaceutical compounds |
| abstract | The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q 1 is a bond or a saturated C 1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONR q or NR q CO where R q is hydrogen or methyl, or R q is a C 1-4 alkylene chain linked to R 1 or a carbon atom of Q 1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q 1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q 2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the G group; and provided that when E is aryl or heteroaryl, then Q 2 is other than a bond; G is hydrogen, NR 2 R 3 , OH or SH provided that when E is aryl or heteroaryl and Q 2 is a bond, then G is hydrogen; R 1 is hydrogen or an aryl or heteroaryl group, with the proviso that when R 1 is hydrogen and G is NR 2 R 3 , then Q 2 is a bond; and R 2 , R 3 R 4 , R 6 and R 8 are as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase P70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase P70S6K is indicated. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194607-A1 |
| priorityDate | 2006-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2584.